Patients with idiopathic pulmonary fibrosis (IPF) frequently have a substantial burden of comorbidities [1]. Antifibrotic therapy is recommended to slow the progression of IPF [2]. Patients receiving antifibrotic therapy frequently receive concomitant medications for the management of comorbidities [1, 3–9]. Previous post hoc analyses of antacids, statins, metformin, anticoagulants and angiotensin modulators in patients with IPF enrolled in phase III randomised controlled trials (RCTs) have generated hypotheses on the impact of these treatments on IPF outcomes [3–9]. The effects of multiple concomitant medications in patients with IPF have been largely unexplored. The objective of the present analyses was to explore the association between use of combinations of frequently prescribed concomitant medications and disease outcomes in patients with IPF. This post hoc exploratory analysis found no clear associations between frequently used concomitant medication combinations and disease progression in 1450 patients with IPF enrolled in phase III trials, but several combinations may require further study. http://bit.ly/2ZzyMXR

中文翻译：

---

特发性肺纤维化的伴随药物和临床结果

特发性肺纤维化 (IPF) 患者经常有大量的合并症负担 [1]。推荐抗纤维化治疗以减缓 IPF 的进展 [2]。接受抗纤维化治疗的患者经常同时接受用于治疗合并症的药物 [1, 3–9]。先前对参加 III 期随机对照试验 (RCT) 的 IPF 患者的抗酸剂、他汀类药物、二甲双胍、抗凝剂和血管紧张素调节剂的事后分析产生了关于这些治疗对 IPF 结果的影响的假设 [3-9]。多种伴随药物对 IPF 患者的影响在很大程度上尚未得到探索。本分析的目的是探讨 IPF 患者使用常用的伴随药物组合与疾病结果之间的关联。这项事后探索性分析发现，在 1450 名参加 III 期试验的 IPF 患者中，常用的伴随药物组合与疾病进展之间没有明确的关联，但几种组合可能需要进一步研究。http://bit.ly/2ZzyMXR